Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Revamps, Buys GSK Cancer Drugs, Sells Animal Health To Lilly

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis is overhauling its pharma business by exchanging selected assets with GlaxoSmithKline and divesting its animal health business to Eli Lilly. Worth more than $25 billion, the complex corporate deal will boost the Swiss group’s oncology unit and create a consumer health joint venture, while divesting its vaccine unit to GSK.

Advertisement

Related Content

Interview: GSK India's Playbook For Vaccines Dominance

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077121

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel